Boston Scientific Corporation vs W W Grainger Inc — how do they compare? Boston Scientific Corporation trades at $51.52 (market cap $74.19B), while W W Grainger Inc trades at $1,311.26 (market cap $61.32B). The key difference: Boston Scientific Corporation is the larger of the two by market cap, and W W Grainger Inc pays a 0.77% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | GWW | |
|---|---|---|
Market Cap | $74.19B | $61.32B |
Sector | Health | Technology |
52-Week High | $108.14 | $1.40K |
52-Week Low | $42.63 | $918.18 |
Enterprise Value | $86.27B | $63.53B |
Dividend Yield | — | 0.77% |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $51.27, up 1.6% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats in 2026, with Q2 EPS of $0.86 exceeding expectations. Revenue grew to $20.07B in 2025 with a 14.4% net margin, while analyst consensus shows 86% buy ratings with a $67.21 price target. Recent insider buying by the CEO and director signals confidence despite near-term guidance challenges.
BSX presents attractive valuation with 44% upside to consensus target, supported by strong fundamentals and institutional support. Key risks include competitive pressures in WATCHMAN and electrophysiology segments, along with elevated RSI levels suggesting potential near-term consolidation. The long-term growth trajectory remains intact with 2026 revenue projected at $21B and 17.5% margins.
W.W. Grainger (GWW) trades at $1,299.53, showing modest daily gains of 0.16%. The stock demonstrates strong fundamental performance with Q2 2026 earnings beating estimates at $12.01 per share versus $11.30 expected, and revenue reaching $5 billion. Technical indicators show bearish momentum with the current price between support at $1,282 and resistance at $1,305. The company raised its full-year 2026 outlook following strong quarterly results driven by margin expansion and market share gains.
GWW presents a mixed investment case with strong profitability metrics (ROE 47.92%, net margin 9.92%) offset by premium valuation (P/E 33.19). Analyst consensus leans cautious with 65.79% hold ratings despite recent earnings beats. Key risks include valuation concerns and competitive pressures in industrial distribution. The $1,320 consensus price target suggests limited upside from current levels, requiring careful monitoring of margin sustainability.
Trailing returns across standard periods
Latest headlines on both assets
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →